COVID-19大流行前后产后阿片类药物处方比较
这项横断面研究纳入2018年7月1日至2020年12月31日分娩单胎活产儿的460 371例私人保险产后妇女,比较2020年3月1日前后的产后阿片类药物处方填充情况。结果显示,2020年3月后分娩者阿片类药物处方填充率较疫情前趋势预测值高2.8个百分点(预测35.0% vs 实际37.8%),每日吗啡毫克当量、人均填充次数及第二类阿片类药物处方填充比例均增加,而处方供应天数及第三类或以上阿片类药物处方填充比例无显著关联。分层分析显示剖宫产者增加幅度大于阴道分娩者。作者认为阿片类药物处方增加可能与产后妇女阿片类药物滥用、阿片类药物使用障碍及阿片类药物相关过量风险增加相关。
要点
- 2020年3月后分娩者阿片类药物处方填充率较疫情前趋势预测值高2.8个百分点(预测35.0% vs 实际37.8%)。
- COVID-19期间每日吗啡毫克当量均值较预测值升高(预测34.1 vs 实际35.8),人均阿片类药物填充次数增加(预测0.49 vs 实际0.54)。
- 第二类阿片类药物处方填充比例较预测值增加(预测28.7% vs 实际31.5%)。
- 处方供应天数及第三类或以上阿片类药物处方填充比例与疫情无显著关联。
- 剖宫产者上述增加幅度大于阴道分娩者。
适用人群与场景
- 2018年7月1日至2020年12月31日分娩单胎活产儿的460 371例私人保险产后妇女。
研究设计与关键结果
- 研究类型为横断面研究,纳入460 371例私人保险产后妇女,比较2020年3月1日前后产后阿片类药物处方填充情况。
- 主要结局为产后6个月内阿片类药物处方填充,包括人均填充次数、每日填充吗啡毫克当量均值、平均供应天数、第二类阿片类药物处方填充百分比、第三类或以上阿片类药物处方填充百分比。
- 2020年3月后分娩者阿片类药物处方填充率较疫情前趋势预测值高2.8个百分点(预测35.0% [95% CI, 34.0%-35.9%] vs 实际37.8% [95% CI, 36.8%-38.7%])。
- COVID-19期间每日吗啡毫克当量均值较预测值升高(预测34.1 [SD 2.0] [95% CI, 33.6-34.7] vs 实际35.8 [SD 1.8] [95% CI, 35.3-36.3])。
- 人均阿片类药物填充次数较预测值增加(预测0.49 [95% CI, 0.48-0.51] vs 实际0.54 [95% CI, 0.51-0.55])。
- 第二类阿片类药物处方填充百分比高于预测值(预测28.7% [95% CI, 27.9%-29.6%] vs 实际31.5% [95% CI, 30.6%-32.3%])。
- 处方供应天数及第三类或以上阿片类药物处方填充百分比与疫情无显著关联。
- 按分娩方式分层,剖宫产者上述增加幅度大于阴道分娩者。
证据类型、等级与局限
- 证据类型:横断面研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为COVID-19大流行开始与产后阿片类药物处方填充显著增加相关,增加可能伴随阿片类药物滥用、阿片类药物使用障碍及阿片类药物相关过量风险增加。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The COVID-19 pandemic substantially disrupted routine health care and exacerbated existing barriers to health care access. Although postpartum women frequently experience pain that interferes with activities of daily living, which is often successfully treated with prescription opioid analgesics, they are also at high risk for opioid misuse.
OBJECTIVE: To compare postpartum opioid prescription fills after the onset of the COVID-19 pandemic in March 2020 with fills before the pandemic.
DESIGN, SETTING, AND PARTICIPANTS: In this cross-sectional study of 460 371 privately insured postpartum women who delivered a singleton live newborn between July 1, 2018, and December 31, 2020, postpartum opioid fills before March 1, 2020, were compared with fills after March 1, 2020. Statistical analysis was performed from December 1, 2021, to September 15, 2022.
EXPOSURE: COVID-19 pandemic onset in March 2020.
MAIN OUTCOMES AND MEASURES: The main outcome was postpartum opioid fills, defined as patient fills of opioid prescriptions during the 6 months after birth. Opioid prescriptions were explored in terms of 5 measures: mean number of fills per person, mean filled morphine milligram equivalents (MMEs) per day, mean days supplied, percentage of patients filling a prescription for a schedule II opioid, and percentage of patients filling a prescription for a schedule III or higher opioid.
RESULTS: Among 460 371 postpartum women (mean [SD] age at delivery, 29.0 [10.8] years), those who gave birth to a single, live newborn after March 2020 were 2.8 percentage points more likely to fill an opioid prescription than expected based on the preexisting trend (forecasted, 35.0% [95% CI, 34.0%-35.9%]; actual, 37.8% [95% CI, 36.8%-38.7%]). The COVID-19 period was also associated with an increase in MMEs per day (forecasted mean [SD], 34.1 [2.0] [95% CI, 33.6-34.7]; actual mean [SD], 35.8 [1.8] [95% CI, 35.3-36.3]), number of opioid fills per patient (forecasted, 0.49 [95% CI, 0.48-0.51]; actual, 0.54 [95% CI, 0.51-0.55]), and percentage of patients filling a schedule II opioid prescription (forecasted, 28.7% [95% CI, 27.9%-29.6%]; actual, 31.5% [95% CI, 30.6%-32.3%]). There was no significant association with days' suppy of opioids per prescription or percentage of patients filling a prescription for a schedule III or higher opioid. Results stratified by delivery modality showed that the observed increases were larger for patients who delivered by cesarean birth than those delivering vaginally.
CONCLUSIONS AND RELEVANCE: This cross-sectional study suggests that the onset of the COVID-19 pandemic was associated with significant increases in postpartum opioid fills. Increases in opioid prescriptions may be associated with increased risk of opioid misuse, opioid use disorder, and opioid-related overdose among postpartum women.
参考来源
- Steuart SR, Lawler EC, Bagwell Adams G, et al. Comparison of Postpartum Opioid Prescriptions Before vs During the COVID-19 Pandemic. JAMA Netw Open. 2023. PMID: 37010867. doi:10.1001/jamanetworkopen.2023.6438
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。